Frank Yocca
Chief Tech/Sci/R&D Officer presso BIOXCEL THERAPEUTICS, INC.
Patrimonio netto: 35 992 $ in data 31/03/2024
Profilo
Frank D.
Yocca is a Member of the National Academy of Medicine (United States) and the Chief Scientific Officer & Senior Vice President at BioXcel Therapeutics, Inc. He previously served as the Executive Director at Bristol-Myers Squibb Pharmaceutical Research Institute from 1984 to 2004.
From 2005 to 2015, he worked as the Vice President-Strategy & Externalization at AstraZeneca PLC.
He then joined BioXcel Corp.
as the Senior Vice President-CNS R&D from 2015 to 2017.
Dr. Yocca completed his undergraduate degree at Manhattan College and holds graduate and doctorate degrees from St. John's University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
04/04/2024 | 12 763 ( 0.04% ) | 35 992 $ | 31/03/2024 |
Posizioni attive di Frank Yocca
Società | Posizione | Inizio |
---|---|---|
BIOXCEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2017 |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Corporate Officer/Principal | - |
Precedenti posizioni note di Frank Yocca
Società | Posizione | Fine |
---|---|---|
BioXcel Corp.
BioXcel Corp. Data Processing ServicesTechnology Services BioXcel Corp. is a biopharmaceutical company based in Branford, CT that utilizes advanced technologies such as AI to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel's AI-enabled platform, EvolverAI, helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process. The private company's family of companies includes BioXcel Therapeutics, Inc., which is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI and its approaches. BioXcel is deeply involved in creating breakthroughs in various categories of diseases. The company was founded by Vimal D. Mehta and Krishnan Nandabalan, with Vimal D. Mehta serving as the CEO since incorporation. | Corporate Officer/Principal | 01/04/2017 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2015 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Director/Board Member | 01/01/2004 |
Formazione di Frank Yocca
Manhattan College | Undergraduate Degree |
St. John's University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
BIOXCEL THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | Commercial Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
BioXcel Corp.
BioXcel Corp. Data Processing ServicesTechnology Services BioXcel Corp. is a biopharmaceutical company based in Branford, CT that utilizes advanced technologies such as AI to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel's AI-enabled platform, EvolverAI, helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process. The private company's family of companies includes BioXcel Therapeutics, Inc., which is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI and its approaches. BioXcel is deeply involved in creating breakthroughs in various categories of diseases. The company was founded by Vimal D. Mehta and Krishnan Nandabalan, with Vimal D. Mehta serving as the CEO since incorporation. | Technology Services |
- Borsa valori
- Insiders
- Frank Yocca